Industry revenue of “manufacture of basic pharmaceutical products“ in Switzerland 2012-2024
With some of the world’s leading pharmaceutical companies such as Novartis and Roche headquartered in the nation, it isn’t surprising to see why the Swiss pharmaceutical products manufacturing industry has been thriving. The industry, which consists of manufacturing basic pharmaceutical products and preparations, was valued at 61 billion U.S. dollars in 2012 and is projected to grow 45 percent by 2024. Moreover, the industry is one of the biggest in Europe, employing over 46,000 people and contributes to over 30 percent of the country’s exports.
Stores tap into medicine reserves amid rising Covid-19 cases
Medical stores in Switzerland have begun tapping into their reserves that were set aside for crisis, as the demand for medicines is soaring due to the rising number of cases in the nation. Demand is particularly high in the canton of Ticino, which is amongst the worst hit, with approximately 470 cases per 100,000 inhabitants, nearly thrice the national rate.
Roche develops new serology test
Roche has announced the development of a new serology test to help identify people who have been infected by Covid-19 virus. It aims to have the test available in countries accepting the CE mark by early May. Moreover, the firm is also working collaboratively with the FDA on a clinical trial to see if certain drugs can work as a treatment for patients hospitalized with severe COVID-19 pneumonia.
Stores tap into medicine reserves amid rising Covid-19 cases
Medical stores in Switzerland have begun tapping into their reserves that were set aside for crisis, as the demand for medicines is soaring due to the rising number of cases in the nation. Demand is particularly high in the canton of Ticino, which is amongst the worst hit, with approximately 470 cases per 100,000 inhabitants, nearly thrice the national rate.
Roche develops new serology test
Roche has announced the development of a new serology test to help identify people who have been infected by Covid-19 virus. It aims to have the test available in countries accepting the CE mark by early May. Moreover, the firm is also working collaboratively with the FDA on a clinical trial to see if certain drugs can work as a treatment for patients hospitalized with severe COVID-19 pneumonia.
